Sarkis Barret Kalindjian

This inventor holds 22 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: James Black Foundation Limited, King's College London, Beecham Group Plc. Active years: 1994-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sarkis Barret Kalindjian. Retrieved from https://idiyas.com/inventor/sarkis-barret-kalindjian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 2)

% Patents Active = 81.8

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 182(Granted Patents)

Location History:

Banstead, GB (1994 - 2002)
Banstead Surrey, GB (2005)
London, GB (2002 - 2016)
Surrey, GB (1998 - 2022)

Company Filing History:

16 out of 20

James Black Foundation Limited

patents

5 out of 196

King's College London

Years Active: 1994-2022

Loading Chart...

Areas of Expertise:

Retinoic Acid Receptor

Histamine H3 Ligands

Gastrin Antagonists

Bicyclo Compounds

Aryl-Amido Compounds

Sulfonamides

Tetrapeptide Derivatives

Pharmaceutical Applications

Cholecystokinin Ligands

Imidazole Derivatives

Hybrid Proteins

Amino Acid Derivatives

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11401265 - Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists (2022-08-02),

2. 10752616 - Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists (2020-08-25),

3. 10385044 - Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists (2019-08-20),

4. 9994559 - Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists (2018-06-12),

5. 9447028 - Therapeutic aryl-amido-aryl compounds and their use (2016-09-20),

6. 7034048 - Gastrin and cholecystokinin receptor ligands (III) (2006-04-25),

7. 6878736 - Histamine H3 receptor ligands (2005-04-12),

8. 6878734 - Gastrin and cholecystokinin receptor ligands(II) (2005-04-12),

9. 6479531 - Gastrin and cholecystokinin receptor ligands (2002-11-12),

10. 6407132 - Substituted imidazole derivatives and their use as histamine H3 receptor ligands (2002-06-18),

11. 6355665 - 1H-4(5)-substituted imidazole derivatives, their preparation and their use as histamine H3 receptor ligands (2002-03-12),

12. 6080871 - Sulfonamides and sulfamides as H.sub.3 receptor antagonists (2000-06-27),

13. 6057311 - Benzodiazonine derivatives binding to cholecystokinin or gastrin (2000-05-02),

14. 5939437 - CCK and gastrin receptor ligands (1999-08-17),

15. 5919829 - Gastrin and cck receptor ligands (1999-07-06),

Title: Sarkis Barret Kalindjian: Innovator in Therapeutic Compounds

Introduction

Sarkis Barret Kalindjian is a notable inventor based in Surrey, GB, recognized for his significant contributions to the field of therapeutic compounds. With an impressive portfolio of 22 patents, Kalindjian has been at the forefront of innovation, particularly in developing substances that target retinoic acid receptors for various medicinal applications.

Latest Patents

Kalindjian's most recent patents focus on bicycloheteroaryl-heteroaryl-benzoic acid compounds, which serve as agonists for retinoic acid receptor beta (RARβ). These compounds, collectively referred to as 'BHBA compounds', demonstrate a selective activation of RARβ (e.g., RARβ2), promoting neurite development, outgrowth, and regeneration. This work has critical implications for treating neurological conditions, including spinal cord injuries, by leveraging the body's own mechanisms to facilitate healing.

Career Highlights

Throughout his career, Sarkis Barret Kalindjian has made significant strides in pharmaceutical innovation. He has worked with reputable organizations such as the James Black Foundation and King's College London, contributing to cutting-edge research and development in the therapeutic domain.

Collaborations

Kalindjian has collaborated with esteemed colleagues, including Ildiko Maria Buck and Michael John Pether, further enhancing the impact of his research through shared expertise and innovative insights.

Conclusion

Sarkis Barret Kalindjian's dedication to advancing therapeutic compounds illustrates his vital role in the scientific community. His innovative inventions promise to make substantial contributions to medicine, particularly in regenerative therapies for neurological injuries. As he continues to develop groundbreaking solutions, his work remains crucial in the pursuit of enhanced treatments for complex health challenges.

Profile summary based on public USPTO records.